Skip to main content
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. — Investor Relations & Filings

Ticker · LXEO ISIN · US52886X1072 US Manufacturing
Open in API
Filings indexed 289 across all filing types
Latest filing 2024-08-12 Interim / Quarterly Rep…
Country US United States of America
Listing US LXEO

About Lexeo Therapeutics, Inc.

https://www.lexeotx.com/

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to developing gene therapies for genetically defined diseases. The company is advancing a diverse pipeline of investigational adeno-associated virus (AAV)-based gene therapy candidates. Its primary areas of focus are rare cardiovascular diseases and APOE4-associated Alzheimer's disease. Lexeo's strategy centers on addressing conditions with high unmet medical needs by leveraging pioneering science, including research originating from institutions such as Weill Cornell Medicine, to develop treatments with curative potential.

Recent filings

Filing Released Lang Actions
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q Quarterly Report filed pursuant to the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2024. It contains detailed financial statements including balance sheets, statements of operations, cash flows, notes to financial statements, and management's discussion and analysis. The document is lengthy (15,000 characters) and includes substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-12 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-12 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 12, 2024, for Lexeo Therapeutics, Inc. It specifically mentions Item 2.02 "Results of Operations and Financial Condition," indicating the company issued a press release announcing financial results for the three and six months ended June 30, 2024. The document states that the press release is furnished as an exhibit and incorporated by reference, and the text itself is a brief current report rather than the full financial results. The length is 3571 characters, which is relatively short and consistent with a current report filing. The document does not contain detailed financial statements or substantive financial data itself but references a press release. According to the classification rules, such a document is a Regulatory Filing (RNS) because it is a current report filing referencing financial results but not the full earnings release or interim report itself. The actual earnings release is attached as an exhibit, not included in the text. Therefore, the best classification is Regulatory Filings (RNS).
2024-08-12 English
SC 13G
Major Shareholding Notification
2024-08-09 English
424B3
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, which includes a prospectus supplement and updates related to a private placement and registration rights agreement. It also announces a press release about interim Phase 1/2 clinical data and a conference call/webcast. The document contains no comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report or Annual Report. Instead, it primarily serves as a regulatory filing to disclose material events and updates. The presence of a press release and corporate presentation as exhibits further supports this classification. Therefore, the document fits best under Regulatory Filings (RNS).
2024-07-15 English
8-K
Investor Presentation Classification · 90% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates that the company issued a press release about positive interim Phase 1/2 clinical data and announced a conference call and webcast to discuss this data. The document includes the press release and a corporate presentation as exhibits. The length is 3385 characters, which is relatively short and the document mainly announces events and attachments rather than providing detailed financial data or the full transcript. The presence of a conference call announcement and a corporate presentation suggests this is an Investor Presentation (IP) type filing. The Form 8-K itself is a regulatory filing, but the content focuses on the presentation and webcast related to clinical data and company updates, which aligns best with Investor Presentation (IP).
2024-07-15 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.